FGP
PTGX icon

Freestone Grove Partners’s Protagonist Therapeutics PTGX Stock Holding History

Freestone Grove Partners’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,644
Closed -$256K – 751
2024
Q4 		$256K Buy
+6,644
New +$290K ﹤0.01% 495

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Freestone Grove Partners's PTGX Position: Q1 2025 in Review

Freestone Grove Partners sold out of Protagonist Therapeutics (PTGX) in Q1 2025, closing a stake of 6,644 shares — an estimated $256K sold.

Freestone Grove Partners first reported a position in PTGX in Q4 2024 and held it in 1 quarter. The position peaked at $256K in Q4 2024. 275 funds tracked by Wall St. Rank hold PTGX as of Q1 2025.

  • Freestone Grove Partners reported no remaining Protagonist Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Freestone Grove Partners sold 6,644 Protagonist Therapeutics shares in Q1 2025, an estimated $256K.
  • Freestone Grove Partners first reported a position in Protagonist Therapeutics in Q4 2024 and held it in 1 quarter.
  • Freestone Grove Partners's Protagonist Therapeutics position peaked at $256K in Q4 2024.
  • 275 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2025.

Based on Freestone Grove Partners's 13F filing for Q1 2025, filed 15 May 2025.